Classification of amyloid-positivity in controls: Comparison of visual read and quantitative approaches

NeuroImage

Volumn 71, Issue , 2013, Pages 207-215

  Cohen, Ann D ^a   Mowrey, Wenzhu ^a   Weissfeld, Lisa A ^a   Aizenstein, Howard J ^a   McDade, Eric ^a   Mountz, James M ^b   Nebes, Robert D ^a   Saxton, Judith A ^a   Snitz, Beth ^a   DeKosky, Steven ^b   Williamson, Jeff ^c   Lopez, Oscar L ^a   Price, Julie C ^a   Mathis, Chester A ^a   Klunk, William E ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF VIRGINIA   (United States)

^c WAKE FOREST BAPTIST HEALTH   (United States)

Author keywords

Amyloid; Cluster analysis; Pittsburgh compound B; Positron emission tomography; Visual read

Indexed keywords

AMYLOID BETA PROTEIN; PITTSBURGH COMPOUND B;

ADULT; AGED; ANALYTIC METHOD; ARTICLE; AUTOMATION; CLASSIFICATION; CLUSTER ANALYSIS; CONTROLLED STUDY; HUMAN; HUMAN EXPERIMENT; ITERATIVE OUTLIER APPROACH; NORMAL HUMAN; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; SEPARATION TECHNIQUE;

ADULT; AGED; AMYLOID; AMYLOIDOSIS; ANILINE COMPOUNDS; BRAIN; CLUSTER ANALYSIS; HUMANS; MIDDLE AGED; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; THIAZOLES;

EID: 84873688351     PISSN: 10538119     EISSN: 10959572     Source Type: Journal    
DOI: 10.1016/j.neuroimage.2013.01.015     Document Type: Article

References (42)

1. Aizenstein H.J., Nebes R.D., Saxton J.A., Price J.C., Mathis C.A., Tsopelas N.D., Ziolko S.K., James J.A., Snitz B.E., Houck P.R., Bi W., Cohen A.D., Lopresti B.J., DeKosky S.T., Halligan E.M., Klunk W.E. Frequent amyloid deposition without significant cognitive impairment among the elderly. Arch. Neurol. 2008, 65(11):1509-1517.
2. Apostolova L.G., Hwang K.S., Andrawis J.P., Green A.E., Babakchanian S., Morra J.H., Cummings J.L., Toga A.W., Trojanowski J.Q., Shaw L.M., Jack C.R., Petersen R.C., Aisen P.S., Jagust W.J., Koeppe R.A., Mathis C.A., Weiner M.W., Thompson P.M. 3D PIB and CSF biomarker associations with hippocampal atrophy in ADNI subjects. Neurobiol. Aging 2010, 31(8):1284-1303.
3. Bi W., Tseng G.C., Weissfeld L.A., Price J.C. Sparse clustering with resampling for subject classification in PET amyloid imaging studies. IEEE Nuclear Science Symposium Conference Record- Valencia MIC12.M-187 2011.
4. Bourgeat P., Chetelat G., Villemagne V.L., Fripp J., Raniga P., Pike K., Acosta O., Szoeke C., Ourselin S., Ames D., Ellis K.A., Martins R.N., Masters C.L., Rowe C.C., Salvado O. Beta-amyloid burden in the temporal neocortex is related to hippocampal atrophy in elderly subjects without dementia. Neurology 2010, 74(2):121-127.
5. Cicchetti D.V., Feinstein A.R. High agreement but low kappa: II. Resolving the paradoxes. J. Clin. Epidemiol. 1990, 43(6):551-558.
6. Cohen J.A. A coefficient of agreement for nominal scales. Educ. Psychol. Meas. 1960, 20:37-46.
7. Cohen A.D., Price J.C., Weissfeld L.A., James J., Rosario B.L., Bi W., Nebes R.D., Saxton J.A., Snitz B.E., Aizenstein H.A., Wolk D.A., DeKosky S.T., Mathis C.A., Klunk W.E. Basal cerebral metabolism may modulate the cognitive effects of a{beta} in mild cognitive impairment: an example of brain reserve. J. Neurosci. 2009, 29(47):14770-14778. 10.1523/jneurosci.3669-09.2009.
8. Devanand D.P., Mikhno A., Pelton G.H., Cuasay K., Pradhaban G., Kumar J.S., Upton N., Lai R., Gunn R.N., Libri V., Liu X., Heertum R.V., Mann J.J., Parsey R.V. Pittsburgh compound B (11C-PIB) and fluorodeoxyglucose (18F-FDG) PET in patients with Alzheimer disease, mild cognitive impairment, and healthy controls. J. Geriatr. Psychiatry Neurol. 2010, 23(3):185-198.
9. Furst A.J., Rabinovici G.D., Rostomian A.H., Steed T., Alkalay A., Racine C., Miller B.L., Jagust W.J. Cognition, glucose metabolism and amyloid burden in Alzheimer's disease. Neurobiol. Aging 2010, 33(2):215-225.
10. Hartigan J.A., Wong M.A. A K-means clustering algorithm. Appl. Stat. 1979, 28:100-108.
11. Hastie T., Tibshirani R., Friedman J. The Elements of Statistical Learning: Data Mining, Inference, and Prediction 2009, vol. 2. Springer, Stanford.
12. Ikonomovic M.D., Klunk W.E., Abrahamson E.E., Mathis C.A., Price J.C., Tsopelas N.D., Lopresti B.J., Ziolko S., Bi W., Paljug W.R., Debnath M.L., Hope C.E., Isanski B.A., Hamilton R.L., DeKosky S.T. Post-mortem correlates of in vivo PiB-PET amyloid imaging in a typical case of Alzheimer's disease. Brain 2008, 131(Pt 6):1630-1645.
13. Jack C.R., Lowe V.J., Senjem M.L., Weigand S.D., Kemp B.J., Shiung M.M., Knopman D.S., Boeve B.F., Klunk W.E., Mathis C.A., Petersen R.C. 11C PiB and structural MRI provide complementary information in imaging of Alzheimer's disease and amnestic mild cognitive impairment. Brain 2008, 131(Pt 3):665-680.
14. Johnson K.A., Gregas M., Becker J.A., Kinnecom C., Salat D.H., Moran E.K., Smith E.E., Rosand J., Rentz D.M., Klunk W.E., Mathis C.A., Price J.C., Dekosky S.T., Fischman A.J., Greenberg S.M. Imaging of amyloid burden and distribution in cerebral amyloid angiopathy. Ann. Neurol. 2007, 62(3):229-234.
15. Kemppainen N.M., Aalto S., Wilson I.A., Nagren K., Helin S., Bruck A., Oikonen V., Kailajarvi M., Scheinin M., Viitanen M., Parkkola R., Rinne J.O. PET amyloid ligand [11C]PIB uptake is increased in mild cognitive impairment. Neurology 2007, 68(19):1603-1606.
16. Klunk W.E., Mathis C.A. Amyloid imaging and (what is "normal") aging. Imaging the Aging Brain 2009, vol. 1:191-245. Oxford University Press, New York.
17. Klunk W.E., Engler H., Nordberg A., Wang Y., Blomqvist G., Holt D.P., Bergström M., Savitcheva I., Huang G.F., Estrada S., Ausén B., Debnath M.L., Barletta J., Price J.C., Sandell J., Lopresti B.J., Wall A., Koivisto P., Antoni G., Mathis C.A., Långström B. Imaging brain amyloid in Alzheimer's disease with Pittsburgh compound-B. Ann. Neurol. 2004, 55(3):306-319.
18. Landis J.R., Koch G.G. The measurement of observer agreement for categorical data. Biometrics 1977, 33:159-174.
19. Lopresti B.J., Klunk W.E., Mathis C.A., Hoge J.A., Ziolko S.K., Lu X., Meltzer C.C., Schimmel K., Tsopelas N.D., Dekosky S.T., Price J.C. simplified quantification of Pittsburgh compound B amyloid imaging PET studies: a comparative analysis. J. Nucl. Med. 2005, 46(12):1959-1972.
20. Mathis, C., Kuller, L., W. K., Snitz, B., Price, J., Weissfeld, L., Rosario, B., Lopresti, B., Saxton, J., Aizenstein, H., McDade, E., Kamboh, M., DeKosky, S., Lopez, O., in press. In vivo assessment of amyloid-β deposition in nondemented very elderly subjects. Ann. Neurol.
21. Meltzer C., Kinahan P., Greer P., et al. Comparative evaluation of MR-based partial volume correction schemes for PET. J. Nucl. Med. 1999, 40:2053-2065.
22. 11C]PIB in a nondemented population: potential antecedent marker of Alzheimer disease. Neurology 2006, 67(3):446-452.
23. Mormino E.C., Kluth J.T., Madison C.M., Rabinovici G.D., Baker S.L., Miller B.L., Koeppe R.A., Mathis C.A., Weiner M.W., Jagust W.J. Episodic memory loss is related to hippocampal-mediated beta-amyloid deposition in elderly subjects. Brain 2009, 132(Pt 5):1310-1323.
24. Mormino E.C., Brandel M.G., Madison C.M., Rabinovici G.D., Marks S., Baker S.L., Jagust W.J. Not quite PIB-positive, not quite PIB-negative: slight PIB elevations in elderly normal control subjects are biologically relevant. NeuroImage 2012, 59(2):1152-1160. 10.1016/j.neuroimage.2011.07.098.
25. Morris J.C., Roe C.M., Xiong C., Fagan A.M., Goate A.M., Holtzman D.M., Mintun M.A. APOE predicts amyloid-beta but not tau Alzheimer pathology in cognitively normal aging. Ann. Neurol. 2010, 67(1):122-131.
26. Ng S., Villemagne V.L., Berlangieri S., Lee S.T., Cherk M., Gong S.J., Ackermann U., Saunder T., Tochon-Danguy H., Jones G., Smith C., O'Keefe G., Masters C.L., Rowe C.C. Visual assessment versus quantitative assessment of 11C-PIB PET and 18F-FDG PET for detection of Alzheimer's disease. J. Nucl. Med. 2007, 48(4):547-552.
27. Petersen R.C. Mild cognitive impairment as a diagnostic entity. J. Intern. Med. 2004, 256(3):183-194.
28. Pike K.E., Savage G., Villemagne V.L., Ng S., Moss S.A., Maruff P., Mathis C.A., Klunk W.E., Masters C.L., Rowe C.C. β-Amyloid imaging and memory in non-demented individuals: evidence for preclinical Alzheimer's disease. Brain 2007, 130(Pt 11):2837-2844.
29. Price J.C., Klunk W.E., Lopresti B.J., Lu X., Hoge J.A., Ziolko S.K., Holt D.P., Meltzer C.C., Dekosky S.T., Mathis C.A. Kinetic modeling of amyloid binding in humans using PET imaging and Pittsburgh compound-B. J. Cereb. Blood Flow Metab. 2005, 25:1528-1547.
30. 11C-PIB PET imaging in Alzheimer disease and frontotemporal lobar degeneration. Neurology 2007, 68(15):1205-1212.
31. Rentz D.M., Locascio J.J., Becker J.A., Moran E.K., Eng E., Buckner R.L., Sperling R.A., Johnson K.A. Cognition, reserve, and amyloid deposition in normal aging. Ann. Neurol. 2010, 67(3):353-364.
32. Resnick S.M., Sojkova J., Zhou Y., An Y., Ye W., Holt D.P., Dannals R.F., Mathis C.A., Klunk W.E., Ferrucci L., Kraut M.A., Wong D.F. Longitudinal cognitive decline is associated with fibrillar amyloid-beta measured by [11C]PiB. Neurology 2010, 74(10):807-815.
33. Rosario B.L., Weissfeld L.A., Laymon C.M., Mathis C.A., Klunk W.E., Berginc M.D., James J.A., Hoge J.A., Price J.C. Inter-rater reliability of manual and automated region-of-interest delineation for PiB PET 2011, Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't.
34. Rowe C.C., Ng S., Ackermann U., Gong S.J., Pike K., Savage G., Cowie T.F., Dickinson K.L., Maruff P., Darby D., Smith C., Woodward M., Merory J., Tochon-Danguy H., O'Keefe G., Klunk W.E., Mathis C.A., Price J.C., Masters C.L., Villemagne V.L. Imaging beta-amyloid burden in aging and dementia. Neurology 2007, 68(20):1718-1725.
35. Rowe C.C., Ellis K.A., Rimajova M., Bourgeat P., Pike K.E., Jones G., Fripp J., Tochon-Danguy H., Morandeau L., O'Keefe G., Price R., Raniga P., Robins P., Acosta O., Lenzo N., Szoeke C., Salvado O., Head R., Martins R., Masters C.L., Ames D., Villemagne V.L. Amyloid imaging results from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging. Neurobiol. Aging 2010, 31(8):1275-1283.
36. Savva G.M., Wharton S.B., Ince P.G., Forster G., Matthews F.E., Brayne C. Age, neuropathology, and dementia. N. Engl. J. Med. 2009, 360(22):2302-2309.
37. Schwertman N.C., de Silva R. Identifying outliers with sequential fences. Comput. Stat. Data Anal. 2007, 51(8):3800-3810.
38. Sperling R.A., Aisen P.S., Beckett L.A., Bennett D.A., Craft S., Fagan A.M., Iwatsubo T., Jack C.R., Kaye J., Montine T.J., Park D.C., Reiman E.M., Rowe C.C., Siemers E., Stern Y., Yaffe K., Carrillo M.C., Thies B., Morrison-Bogorad M., Wagster M.V., Phelps C.H. Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 2011, 7(3):280-292.
39. Spitzer R.L., Fleiss J.L. A re-analysis of the reliability of psychiatric diagnosis. Br. J. Psychiatry 1974, 125:341-372.
40. Suotunen T., Hirvonen J., Immonen-Raiha P., Aalto S., Lisinen I., Arponen E., Teras M., Koski K., Sulkava R., Seppanen M., Rinne J.O. Visual assessment of [(11)C]PIB PET in patients with cognitive impairment. Eur. J. Nucl. Med. Mol. Imaging 2010, 37(6):1141-1147.
41. Tolboom N., van der Flier W.M., Boverhoff J., Yaqub M., Wattjes M.P., Raijmakers P.G., Barkhof F., Scheltens P., Herholz K., Lammertsma A.A., van Berckel B.N. Molecular imaging in the diagnosis of Alzheimer's disease: visual assessment of [11C]PIB and [18F]FDDNP PET images. J. Neurol. Neurosurg. Psychiatry 2010, 81(8):882-884.
42. Witten D.M., Tibshirani R. A framework for feature selection in clustering. J. Am. Stat. Assoc. 2010, 105(490):713-726.